Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer
作者机构：Central LaboratoryAffiliated Fuda Cancer HospitalJinan UniversityGuangzhou 510665Guangdong ProvinceChina Department of OncologyAffiliated Fuda Cancer HospitalJinan UniversityGuangzhou 510665Guangdong ProvinceChina Department of Interventional RadiologyAffiliated Fuda Cancer HospitalJinan UniversityGuangzhou 510665Guangdong ProvinceChina
出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)
年 卷 期：2020年第8卷第22期
页 面：5564-5575页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：Supported by International Science Foundation of Affiliated Fuda Cancer Hospital Jinan University No.Y2018-ZD-01
主 题：Irreversible electroporation Gemcitabine Locally advanced pancreatic cancer Overall survival Progression free survival Prognostic factors
摘 要：BACKGROUND Locally advanced pancreatic cancer(LAPC)is a common malignant digestive system tumor that ranks as the fourth leading cause of cancer-related death in the *** prognosis of LAPC is poor even after standard *** electroporation(IRE)is a novel ablative strategy for *** studies have confirmed the safety of *** date,no prospective studies have been performed to investigate the therapeutic efficacy of conventional gemcitabine(GEM)plus concurrent *** To compare the therapeutic efficacy between conventional GEM plus concurrent IRE and GEM alone for *** From February 2016 to September 2017,a total of 68 LAPC patients were treated with GEM plus concurrent IRE(n=33)or GEM alone(n=35).Overall survival(OS),progression free survival(PFS),and procedure-related complications were compared between the two *** analyses were performed to identify any prognostic *** There were no treatment-related *** technical success rate of IRE ablation was 100%.The GEM+IRE group had a significantly longer OS from the time of diagnosis of LAPC(19.8 mo vs 9.3 mo,P0.0001)than the GEM alone *** GEM+IRE group had a significantly longer PFS(8.3 mo vs 4.7 mo,P0.0001)than the GEM alone *** volume less than 37 cm3 and GEM plus concurrent IRE were identified as significant favorable factors for both the OS and *** Gemcitabine plus concurrent IRE is an effective treatment for patients with LAPC.
维普期刊数据库